Skip to main content
Erschienen in: Diabetologia 5/2010

01.05.2010 | Review

The use of metformin in type 1 diabetes: a systematic review of efficacy

verfasst von: S. Vella, L. Buetow, P. Royle, S. Livingstone, H. M. Colhoun, J. R. Petrie

Erschienen in: Diabetologia | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

As adding metformin to insulin therapy has been advocated in type 1 diabetes, we conducted a systematic review of published clinical trials and clinical trial databases to assess the effects on HbA1c, weight, insulin-dose requirement and adverse effects.

Methods

We constructed evidence tables and fitted a fixed-effects model (inverse variance method) in order to assess heterogeneity between studies and give a crude measure of each overall treatment effect.

Results

Of 197 studies identified, nine involved randomisation with informed consent of patients with type 1 diabetes to metformin (vs placebo or comparator) in either a parallel or crossover design for at least 1 week. We noted marked heterogeneity in study design, drug dose, age of participants and length of follow-up. Metformin was associated with reductions in: (1) insulin-dose requirement (5.7–10.1 U/day in six of seven studies); (2) HbA1c (0.6–0.9% in four of seven studies); (3) weight (1.7–6.0 kg in three of six studies); and (4) total cholesterol (0.3–0.41 mmol/l in three of seven studies). Metformin was well tolerated, albeit with a trend towards increased hypoglycaemia. Formal estimates of combined effects from the five trials which reported appropriate data indicated a significant reduction in insulin dose (6.6 U/day, p < 0.001) but no significant reduction in HbA1c (absolute reduction 0.11%, p = 0.42). No reported trials included cardiovascular outcomes.

Conclusions/interpretation

Metformin reduces insulin-dose requirement in type 1 diabetes but it is unclear whether this is sustained beyond 1 year and whether there are benefits for cardiovascular and other key clinical outcomes.
Literatur
1.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
2.
Zurück zum Zitat Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD (1998) Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 280:140–146CrossRefPubMed Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD (1998) Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 280:140–146CrossRefPubMed
3.
Zurück zum Zitat Sibley SD, Palmer JP, Hirsch IB, Brunzell JD (2003) Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes. J Clin Endocrinol Metab 88:3379–3384CrossRefPubMed Sibley SD, Palmer JP, Hirsch IB, Brunzell JD (2003) Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes. J Clin Endocrinol Metab 88:3379–3384CrossRefPubMed
5.
Zurück zum Zitat The National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes. National clinical guidelines for management in primary and secondary care (update). Royal College of Physicians, London The National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes. National clinical guidelines for management in primary and secondary care (update). Royal College of Physicians, London
6.
Zurück zum Zitat Nathan DM, Buse JB, Davidson MB et al (2009) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30CrossRefPubMed Nathan DM, Buse JB, Davidson MB et al (2009) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30CrossRefPubMed
7.
Zurück zum Zitat International Diabetes Federation Clinical Guidelines Task Force (2005) Global guidelines for type 2 diabetes. International Diabetes Federation, Brussels International Diabetes Federation Clinical Guidelines Task Force (2005) Global guidelines for type 2 diabetes. International Diabetes Federation, Brussels
8.
Zurück zum Zitat Schimmack G, Defronzo RA, Musi N (2006) AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8:591–602CrossRefPubMed Schimmack G, Defronzo RA, Musi N (2006) AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8:591–602CrossRefPubMed
9.
Zurück zum Zitat Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22:215–224CrossRefPubMed Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22:215–224CrossRefPubMed
10.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
11.
Zurück zum Zitat Wright AD, Cull CA, Macleod KM, Holman RR (2006) Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73. J Diabetes Complications 20:395–401CrossRefPubMed Wright AD, Cull CA, Macleod KM, Holman RR (2006) Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73. J Diabetes Complications 20:395–401CrossRefPubMed
12.
Zurück zum Zitat Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443CrossRefPubMed Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443CrossRefPubMed
13.
Zurück zum Zitat Bolen S, Feldman L, Vassy J et al (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386–399PubMed Bolen S, Feldman L, Vassy J et al (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386–399PubMed
14.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed
15.
Zurück zum Zitat Pang TT, Narendran P (2008) Addressing insulin resistance in type 1 diabetes. Diabet Med 25:1015–1024CrossRefPubMed Pang TT, Narendran P (2008) Addressing insulin resistance in type 1 diabetes. Diabet Med 25:1015–1024CrossRefPubMed
16.
Zurück zum Zitat Lund SS, Tarnow L, Astrup AS et al (2008) Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One 3:e3363CrossRefPubMed Lund SS, Tarnow L, Astrup AS et al (2008) Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One 3:e3363CrossRefPubMed
17.
Zurück zum Zitat Walravens PA, Chase PH, Klingensmith GJ, Ellison M, Cornell C, Monahan K (2000) Low dose metformin in adolescents with type 1 diabetes mellitus: a double blind, controlled study. Diabetes 49(Suppl 1):A128 (Abstract) Walravens PA, Chase PH, Klingensmith GJ, Ellison M, Cornell C, Monahan K (2000) Low dose metformin in adolescents with type 1 diabetes mellitus: a double blind, controlled study. Diabetes 49(Suppl 1):A128 (Abstract)
18.
Zurück zum Zitat Lacigova S, Rusavy Z, Jankovec Z, Kyselova P (2001) Metformin in the treatment of type 1 diabetics—a placebo controlled study. Cas Lek Cesk 140:302–306PubMed Lacigova S, Rusavy Z, Jankovec Z, Kyselova P (2001) Metformin in the treatment of type 1 diabetics—a placebo controlled study. Cas Lek Cesk 140:302–306PubMed
19.
20.
Zurück zum Zitat Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D (2003) Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 26:138–143CrossRefPubMed Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D (2003) Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 26:138–143CrossRefPubMed
21.
Zurück zum Zitat Särnblad S, Kroon M, Aman J (2003) Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 149:323–329CrossRefPubMed Särnblad S, Kroon M, Aman J (2003) Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 149:323–329CrossRefPubMed
22.
Zurück zum Zitat Moon RJ, Bascombe LA, Holt RI (2007) The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes Metab 9:143–145CrossRefPubMed Moon RJ, Bascombe LA, Holt RI (2007) The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes Metab 9:143–145CrossRefPubMed
23.
Zurück zum Zitat Khan AS, McLoughney CR, Ahmed AB (2006) The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med 23:1079–1084CrossRefPubMed Khan AS, McLoughney CR, Ahmed AB (2006) The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med 23:1079–1084CrossRefPubMed
24.
Zurück zum Zitat Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions 5.0.1 [updated September 2008]. In: The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org (accessed 31 July 2009) Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions 5.0.1 [updated September 2008]. In: The Cochrane Collaboration, 2008. Available from www.​cochrane-handbook.​org (accessed 31 July 2009)
25.
Zurück zum Zitat Gin H, Messerchmitt C, Brottier E, Aubertin J (1985) Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism 34:923–925CrossRefPubMed Gin H, Messerchmitt C, Brottier E, Aubertin J (1985) Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism 34:923–925CrossRefPubMed
26.
Zurück zum Zitat Keen H, Collins ACG, Bending JJ (1987) Metformin increases response to insulin in type-1 (insulin-dependent) diabetes. Diabetologia 30:A538 (Abstract) Keen H, Collins ACG, Bending JJ (1987) Metformin increases response to insulin in type-1 (insulin-dependent) diabetes. Diabetologia 30:A538 (Abstract)
27.
Zurück zum Zitat Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMed Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMed
28.
Zurück zum Zitat Ahmed AE, Home PD, Marshall SM (2001) Effect of metformin in blood glucose control on people with type 1 diabetes. Diabetes 50(Suppl 2):A430 (Abstract) Ahmed AE, Home PD, Marshall SM (2001) Effect of metformin in blood glucose control on people with type 1 diabetes. Diabetes 50(Suppl 2):A430 (Abstract)
29.
Zurück zum Zitat Coscelli C, Palmari V, Saccardi F, Alpi O, Bonora E (1984) Evidence that metformin addition to insulin induces an amelioration of glycemic profile in type I (insulin-dependent) diabetes mellitus. Curr Ther Res 35:1058–1064 Coscelli C, Palmari V, Saccardi F, Alpi O, Bonora E (1984) Evidence that metformin addition to insulin induces an amelioration of glycemic profile in type I (insulin-dependent) diabetes mellitus. Curr Ther Res 35:1058–1064
30.
Zurück zum Zitat Desmangles J, Buchlis JG, Shine B, Quattrin T (2000) Is metformin a useful adjunct to insulin therapy in adolescents with type 1 diabetes in poor control? Endocrine Society Meeting: 444 (Abstract) Desmangles J, Buchlis JG, Shine B, Quattrin T (2000) Is metformin a useful adjunct to insulin therapy in adolescents with type 1 diabetes in poor control? Endocrine Society Meeting: 444 (Abstract)
31.
Zurück zum Zitat Gin H, Freyburger G, Boisseau M, Aubertin J (1989) Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Res Clin Pract 6:61–67CrossRefPubMed Gin H, Freyburger G, Boisseau M, Aubertin J (1989) Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Res Clin Pract 6:61–67CrossRefPubMed
32.
Zurück zum Zitat Gomez R, Mokhashi MH, Rao J et al (2002) Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. J Pediatr Endocrinol Metab 15:1147–1151PubMed Gomez R, Mokhashi MH, Rao J et al (2002) Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. J Pediatr Endocrinol Metab 15:1147–1151PubMed
33.
Zurück zum Zitat Gottlieb PA, Ellis SL, Lopez P, Gutin R, Garg SK (2007) Metformin improved glycaemic control in patients with type 1 diabetes. Diabetes 56:A574 (Abstract)CrossRef Gottlieb PA, Ellis SL, Lopez P, Gutin R, Garg SK (2007) Metformin improved glycaemic control in patients with type 1 diabetes. Diabetes 56:A574 (Abstract)CrossRef
34.
Zurück zum Zitat Gunton JE, Twigg SM (2003) Metformin use as an adjunct to insulin treatment. Med J Aust 178:591–592PubMed Gunton JE, Twigg SM (2003) Metformin use as an adjunct to insulin treatment. Med J Aust 178:591–592PubMed
35.
Zurück zum Zitat Janssen M, Rillaerts E, De Leeuw I (1991) Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother 45:363–367CrossRefPubMed Janssen M, Rillaerts E, De Leeuw I (1991) Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother 45:363–367CrossRefPubMed
36.
Zurück zum Zitat Lacigova S, Rusavy Z, Kyselova P, Jankovec Z, Karova R, Cechurova D (2001) Short-term and long-term effect of metformin in type 1 diabetics. Vnitr Lek 47:81–86PubMed Lacigova S, Rusavy Z, Kyselova P, Jankovec Z, Karova R, Cechurova D (2001) Short-term and long-term effect of metformin in type 1 diabetics. Vnitr Lek 47:81–86PubMed
37.
Zurück zum Zitat Lestradet H, Labram C, Gregoire J, Billaud L, Deschamps I (1966) The limits of effectiveness of dimethylbiguanide in some cases of minor diabetes mellitus, in young patients, apparently well controlled by this sole treatment. Diabetes 14:157–171PubMed Lestradet H, Labram C, Gregoire J, Billaud L, Deschamps I (1966) The limits of effectiveness of dimethylbiguanide in some cases of minor diabetes mellitus, in young patients, apparently well controlled by this sole treatment. Diabetes 14:157–171PubMed
38.
Zurück zum Zitat Melga P (1989) Usefulness and rationale of combined therapy with insulin and metformin in insulin-dependent diabetes (type I). G Ital Diabetol 9:247–253 Melga P (1989) Usefulness and rationale of combined therapy with insulin and metformin in insulin-dependent diabetes (type I). G Ital Diabetol 9:247–253
39.
Zurück zum Zitat Pagano G, Tagliaferro V, Carta Q et al (1983) Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia 24:351–354CrossRefPubMed Pagano G, Tagliaferro V, Carta Q et al (1983) Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia 24:351–354CrossRefPubMed
40.
Zurück zum Zitat Ravina A, Minuchin O (1990) Bedtime administration of metformin may reduce insulin requirements. Harefuah 119:200–203PubMed Ravina A, Minuchin O (1990) Bedtime administration of metformin may reduce insulin requirements. Harefuah 119:200–203PubMed
41.
Zurück zum Zitat Tan AB, Bandyopadhyay S, Brake J, Weston PJ (2006) Effects of metformin in type 1 diabetes mellitus. Diab Med 23(Suppl 2):111 (Abstract) Tan AB, Bandyopadhyay S, Brake J, Weston PJ (2006) Effects of metformin in type 1 diabetes mellitus. Diab Med 23(Suppl 2):111 (Abstract)
42.
Zurück zum Zitat Urakami T, Morimoto S, Owada M, Harada K (2005) Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus. Pediatr Int 47:430–433CrossRefPubMed Urakami T, Morimoto S, Owada M, Harada K (2005) Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus. Pediatr Int 47:430–433CrossRefPubMed
43.
44.
Zurück zum Zitat Alves C (2006) Metformin as an adjunctive therapy to insulin in adolescents with type 1 diabetes mellitus. Revista Brasileira de Medicina 63:539–543 Alves C (2006) Metformin as an adjunctive therapy to insulin in adolescents with type 1 diabetes mellitus. Revista Brasileira de Medicina 63:539–543
45.
Zurück zum Zitat Daniel JR, Hagmeyer KO (1997) Metformin and insulin: is there a role for combination therapy? Ann Pharmacother 31:474–480PubMed Daniel JR, Hagmeyer KO (1997) Metformin and insulin: is there a role for combination therapy? Ann Pharmacother 31:474–480PubMed
46.
Zurück zum Zitat Faichney JD, Tate PW (2003) Metformin in type 1 diabetes: is this a good or bad idea? Diabetes Care 26:1655CrossRefPubMed Faichney JD, Tate PW (2003) Metformin in type 1 diabetes: is this a good or bad idea? Diabetes Care 26:1655CrossRefPubMed
47.
Zurück zum Zitat Fossati P, Fontaine P, Beuscart R (1985) Value of metformin-insulin association in the treatment of insulin-dependent diabetes. Diabete Metab 11:396–398PubMed Fossati P, Fontaine P, Beuscart R (1985) Value of metformin-insulin association in the treatment of insulin-dependent diabetes. Diabete Metab 11:396–398PubMed
48.
Zurück zum Zitat Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal JP (1995) The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 11(Suppl 1):S63–S67 (Abstract)PubMed Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal JP (1995) The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabetes Metab Rev 11(Suppl 1):S63–S67 (Abstract)PubMed
49.
Zurück zum Zitat Jefferies CA, Hamilton J, Daneman D (2004) Potential adjunctive therapies in adolescents with type 1 diabetes mellitus. Treat Endocrinol 3:337–343CrossRefPubMed Jefferies CA, Hamilton J, Daneman D (2004) Potential adjunctive therapies in adolescents with type 1 diabetes mellitus. Treat Endocrinol 3:337–343CrossRefPubMed
50.
Zurück zum Zitat Meyer L, Guerci B (2003) Metformin and insulin in type 1 diabetes: the first step. Diabetes Care 26:1655–1656CrossRefPubMed Meyer L, Guerci B (2003) Metformin and insulin in type 1 diabetes: the first step. Diabetes Care 26:1655–1656CrossRefPubMed
51.
Zurück zum Zitat Rachmiel M, Perlman K, Daneman D (2005) Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am 52:1651–1675CrossRefPubMed Rachmiel M, Perlman K, Daneman D (2005) Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am 52:1651–1675CrossRefPubMed
52.
Zurück zum Zitat Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 9:799–812CrossRefPubMed Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab 9:799–812CrossRefPubMed
53.
Zurück zum Zitat Slama G (1991) The insulin sparing effect of metformin in insulin-treated diabetic patients. Diabete Metab 17:241–243PubMed Slama G (1991) The insulin sparing effect of metformin in insulin-treated diabetic patients. Diabete Metab 17:241–243PubMed
54.
Zurück zum Zitat Ferguson AW, De La Harpe PL, Farquhar JW (1961) Dimethyldiguanide in the treatment of diabetic children. Lancet 1:1367–1369CrossRefPubMed Ferguson AW, De La Harpe PL, Farquhar JW (1961) Dimethyldiguanide in the treatment of diabetic children. Lancet 1:1367–1369CrossRefPubMed
55.
Zurück zum Zitat Pirart J (1971) Failure of the biguanides to improve the control of unstable diabetes treated with insulin. Diabetologia 7:283–286CrossRefPubMed Pirart J (1971) Failure of the biguanides to improve the control of unstable diabetes treated with insulin. Diabetologia 7:283–286CrossRefPubMed
56.
Zurück zum Zitat Rizkalla SW, Elgrably F, Tchobroutsky G, Slama G (1986) Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients. Diabete Metab 12:219–224PubMed Rizkalla SW, Elgrably F, Tchobroutsky G, Slama G (1986) Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients. Diabete Metab 12:219–224PubMed
57.
Zurück zum Zitat Slama G, Gin H, Weissbrodt P, Poynard T, Vexiau P, Klein JC (1981) Metformin reduces post-prandial insulin needs in type-1 diabetics—assessment by the artificial pancreas. Diabetologia 21:329 (Abstract) Slama G, Gin H, Weissbrodt P, Poynard T, Vexiau P, Klein JC (1981) Metformin reduces post-prandial insulin needs in type-1 diabetics—assessment by the artificial pancreas. Diabetologia 21:329 (Abstract)
58.
Zurück zum Zitat Tagliaferro V, Pagano G, Carta Q, Vitelli F, Pisu E, Cocuzza E (1981) Insulin sparing effect of metformin on insulin requirement of IDDM assessed by artificial pancreas (Biostator Ames). Diabetologia 21:333 (Abstract) Tagliaferro V, Pagano G, Carta Q, Vitelli F, Pisu E, Cocuzza E (1981) Insulin sparing effect of metformin on insulin requirement of IDDM assessed by artificial pancreas (Biostator Ames). Diabetologia 21:333 (Abstract)
59.
Zurück zum Zitat Meyer L, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B (1999) Continuous subcutaneous insulin infusion in type 1 diabetes: insulin-sparing effect of metformin. Diabetologia 42(Suppl 1):A226 (Abstract) Meyer L, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B (1999) Continuous subcutaneous insulin infusion in type 1 diabetes: insulin-sparing effect of metformin. Diabetologia 42(Suppl 1):A226 (Abstract)
60.
Zurück zum Zitat Jacobsen PK, Lund SS, Tarnow L et al (2007) Impact of metformin treatment on glycaemic control and cardiovascular risk-factors in patients with poorly controlled type 1 diabetes (T1DM). Diabetologia 50(Suppl 1):S107 (Abstract) Jacobsen PK, Lund SS, Tarnow L et al (2007) Impact of metformin treatment on glycaemic control and cardiovascular risk-factors in patients with poorly controlled type 1 diabetes (T1DM). Diabetologia 50(Suppl 1):S107 (Abstract)
61.
Zurück zum Zitat Leblanc H, Marre M, Billault B, Passa P (1987) Value of combined subcutaneous infusion of insulin and metformin in 10 insulin-dependent obese diabetics. Diabete Metab 13:613–617PubMed Leblanc H, Marre M, Billault B, Passa P (1987) Value of combined subcutaneous infusion of insulin and metformin in 10 insulin-dependent obese diabetics. Diabete Metab 13:613–617PubMed
62.
Zurück zum Zitat Gin H, Slama G, Weissbrodt P et al (1982) Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia 23:34–36CrossRefPubMed Gin H, Slama G, Weissbrodt P et al (1982) Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia 23:34–36CrossRefPubMed
63.
Zurück zum Zitat Meyer L, Bohme P, Delbachian I et al (2002) The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 25:2153–2158CrossRefPubMed Meyer L, Bohme P, Delbachian I et al (2002) The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 25:2153–2158CrossRefPubMed
64.
Zurück zum Zitat Schatz H, Winkler G, Jonatha EM, Pfeiffer EF (1975) Studies on juvenile-type diabetes in children. Assessment of control under treatment with constant and variable doses of insulin with or without addition of biguanides. Diabete Metab 1:211–220PubMed Schatz H, Winkler G, Jonatha EM, Pfeiffer EF (1975) Studies on juvenile-type diabetes in children. Assessment of control under treatment with constant and variable doses of insulin with or without addition of biguanides. Diabete Metab 1:211–220PubMed
65.
Zurück zum Zitat Jacobsen IB, Henriksen JE, Beck-Nielsen H (2009) The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol 105:145–149CrossRefPubMed Jacobsen IB, Henriksen JE, Beck-Nielsen H (2009) The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol 105:145–149CrossRefPubMed
66.
Zurück zum Zitat Lund SS, Tarnow L, Astrup AS et al (2009) Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab 11:966–977CrossRefPubMed Lund SS, Tarnow L, Astrup AS et al (2009) Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab 11:966–977CrossRefPubMed
67.
Zurück zum Zitat Kearney PM, Blackwell L, Collins R et al (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117–125CrossRefPubMed Kearney PM, Blackwell L, Collins R et al (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117–125CrossRefPubMed
68.
Zurück zum Zitat Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT (2004) The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 256:1–14CrossRefPubMed Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT (2004) The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 256:1–14CrossRefPubMed
69.
Zurück zum Zitat Salpeter S, Greyber E, Pasternak G, Salpeter E (2003) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev: CD002967 Salpeter S, Greyber E, Pasternak G, Salpeter E (2003) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev: CD002967
70.
Zurück zum Zitat Petrie JR (2009) Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 360:416–417CrossRefPubMed Petrie JR (2009) Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 360:416–417CrossRefPubMed
71.
Zurück zum Zitat Kooy A, de Jager J, Lehert P et al (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169:616–625CrossRefPubMed Kooy A, de Jager J, Lehert P et al (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169:616–625CrossRefPubMed
72.
Zurück zum Zitat Jadhav S, Ferrell W, Greer IA, Petrie JR, Cobbe SM, Sattar N (2006) Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 48:956–963CrossRefPubMed Jadhav S, Ferrell W, Greer IA, Petrie JR, Cobbe SM, Sattar N (2006) Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 48:956–963CrossRefPubMed
73.
Zurück zum Zitat Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP (2003) Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 278:31629–31639CrossRefPubMed Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP (2003) Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 278:31629–31639CrossRefPubMed
74.
Zurück zum Zitat Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328–341CrossRefPubMed Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328–341CrossRefPubMed
75.
Zurück zum Zitat Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S (2004) Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 64:225–228CrossRefPubMed Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S (2004) Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 64:225–228CrossRefPubMed
76.
Zurück zum Zitat Zou MH, Wu Y (2008) AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 35:535–545CrossRefPubMed Zou MH, Wu Y (2008) AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 35:535–545CrossRefPubMed
77.
Zurück zum Zitat Laing SP, Swerdlow AJ, Carpenter LM et al (2003) Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 34:418–421CrossRefPubMed Laing SP, Swerdlow AJ, Carpenter LM et al (2003) Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 34:418–421CrossRefPubMed
78.
Zurück zum Zitat Laing SP, Swerdlow AJ, Slater SD et al (2003) Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46:760–765CrossRefPubMed Laing SP, Swerdlow AJ, Slater SD et al (2003) Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46:760–765CrossRefPubMed
79.
Zurück zum Zitat Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. Diabetologia 49:660–666CrossRefPubMed Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. Diabetologia 49:660–666CrossRefPubMed
80.
Zurück zum Zitat Morris AD, Boyle DI, MacAlpine R et al (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524–528PubMed Morris AD, Boyle DI, MacAlpine R et al (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524–528PubMed
81.
Zurück zum Zitat Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625CrossRefPubMed Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620–1625CrossRefPubMed
Metadaten
Titel
The use of metformin in type 1 diabetes: a systematic review of efficacy
verfasst von
S. Vella
L. Buetow
P. Royle
S. Livingstone
H. M. Colhoun
J. R. Petrie
Publikationsdatum
01.05.2010
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 5/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1636-9

Weitere Artikel der Ausgabe 5/2010

Diabetologia 5/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.